Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d'etude des lymphomes de l'adulte

Journal of Clinical Oncology

Volumn 23, Issue 18, 2005, Pages 4117-4126

  Feugier, Pierre ^a   Van Hoof, A ^a   Sebban, C ^a   Solal Celigny, P ^a   Bouabdallah, R ^a   Ferme C ^a   Christian, B ^a   Lepage, E ^a   Tilly, H ^a   Morschhauser, F ^a   Gaulard, P ^a   Salles, G ^a   Bosly, A ^a   Gisselbrecht, C ^a   Reyes, F ^a   Coiffier, B ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFECTION COMPLICATION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; LOG RANK TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENESCENCE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; DISEASE COURSE; MIDDLE AGED; SALVAGE THERAPY; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 23044503407     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.131     Document Type: Article

References (27)

1. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
2. Coiffier B: Increasing chemotherapy intensity in aggressive lymphomas: A renewal? J Clin Oncol 21:2457-2459, 2003
3. Coiffier B: Treatment of aggressive lymphomas, disseminated cases, in Perry MC (ed): 2003 ASCO Educational Book. Alexandria, VA, American Society of Clinical Oncology, 2003, pp 606-611
4. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-A Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 18:3025-3030, 2000
5. Tilly H, Lepage E, Coiffier B, et al: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102: 4284-4289, 2003
6. Cartron G, Watier H, Golay J, et al: From the bench to the bedside: Ways to improve rituximab efficacy. Blood 104:2635-2642, 2004
7. Cragg MS, Glennie MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103:2738-2743, 2004
8. Eisenbeis CF, Caligiuri MA, Byrd JC: Rituximab: Converging mechanisms of action in non-Hodgkin's lymphoma? Clin Cancer Res 9:5810-5812, 2003
9. Smith MR: Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 22:7359-7368, 2003
10. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
11. Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001
12. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
13. Jaffe ES, Harris NL, Stein H, et al: World Health Organization Classification of Tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France, International Agency for Research on Cancer, 2001
14. Shipp MA, Harrington DP, Anderson JR, et al: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
15. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999
16. Habermann TM, Weller EA, Morrison VA, et al: Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 102:6a, 2003 (suppl 1)
17. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC). Blood 102:29a, 2003 (suppl 1)
18. Pfreundschuh MG, Trümper L, Ma D, et al: Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab: Early stopping after the first interim analysis. Proc Am Soc Clin Oncol 23:556, 2004 (abstr 6500)
19. Dreyling MH, Forstpointner R, Repp R, et al: Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 102:103a, 2003 (suppl 1; abstr 351)
20. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
21. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
22. Shipp MA, Abeloff MD, Antman KH, et al: International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury. J Clin Oncol 17:423-429, 1999
23. Coiffier B: Chemotherapy combined with monoclonal antibodies in the treatment of patients with diffuse large B-cell lymphoma, in DeVita VT, Hellman S, Rosenberg SA (eds): Progress in Oncology 2004. Sudbury, MA, Jones & Bartlett, 2005, pp 220-235
24. Coiffier B: Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin Oncol 31:7-11, 2004
25. Wilson WH, Gutierrez M, O'Connor P, et al: The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29:41-47, 2002
26. Coiffier B: Dose intensity or monoclonal antibody in first-line treatment. Hematol J 5:S154-S158, 2004 (suppl 3)
27. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004